Patrick Ryan Potts

This study shows that MAGEA3/6 proteins in pancreatic cancer cells enhance metabolic flexibility by regulating glycolysis and mitochondrial metabolism, revealing therapeutic vulnerabilities.

This study develops VHL molecular glues that selectively degrade caspase-2, expanding the substrate range of VHL-based degraders and providing tools to study caspase-2's role in apoptosis and stress.

This study identifies MAGE-A10 as a cancer-specific protein that stabilizes KAT2A and KAT2B acetyltransferases, leading to increased histone acetylation and tumorigenesis.

This paper introduces LYMTACs, small molecules that use lysosomal membrane proteins to target and degrade membrane proteins, showing effectiveness against KRASG12D.

This study identifies MAGE antigens as markers of tumor heterogeneity and species-specificity in group 3 medulloblastoma, showing their role in cell survival and potential as therapeutic targets.

This paper identifies a covalent compound EN1441 that selectively degrades AR and AR-V7 in androgen-independent prostate cancer cells by targeting an intrinsically disordered cysteine.

The paper discovers a VHL molecular glue degrader of GEMIN3 using Picowell RNA-seq screening, showing how it targets GEMIN3 for degradation through ternary complex formation.

The paper demonstrates VIPER-TACs, which use viral E3 ligases to selectively degrade disease-specific proteins, reducing toxicity and expanding therapeutic options for targeted protein degradation.